Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Uzupełniające ukierunkowane zarządzanie temperaturą w ostrym ciężkim zatruciu tlenkiem węgla

8 listopada 2026 zaktualizowane przez: Yong Sung Cha, Wonju Severance Christian Hospital

Ukierunkowane zarządzanie temperaturą w połączeniu z terapią tlenem hiperbarycznym w ostrym i ciężkim zatruciu tlenkiem węgla: wieloośrodkowe, randomizowane, kontrolowane badanie kliniczne (badanie TTM-COHB)

This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

CO-poisoned patients are identified by medical history and carboxyhemoglobin (CO-Hb) value >5% (>10% in smokers). Patients presenting with acute CO poisoning will receive one HBO. ASCOP is defined as mental status showing response to painful stimulus or unresponsiveness requiring intubation for airway protection and ventilation support at the emerency department, and persistence of depressed mental status despite the HBO. After HBO treatment, eligible patients who provide consent will be randomly allocated to receive hypothermia, or normothermia treatment administered in a open label fashion except for blinding of outcome assessor.

Outcome measures will be administered at 1 month and 6 months after CO exposure. In addition, we will examine the differences in serum markers and mortality between the hypothermia and normothermia groups.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

39

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Gangwon-do
      • Wŏnju, Gangwon-do, Korea Południowa, 26426
        • Wonju Severance Christian Hospital
    • Incheon
      • Incheon, Incheon, Korea Południowa, 22332
        • Inha University Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

19 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • ≥ 19 years.
  • Patients who received HBO within 24 hours for acute CO poisoning.
  • Patients who meet the definition of ASCOP (Patients incapable verbal obey after HBO).
  • Signed informed consent prior to study entry.

Exclusion Criteria:

  • Cardiac arrest before HBO
  • Previous neurocognitive disorders
  • Life-threatening underlying disease (ex: advanced cancer)
  • Evidence of co-ingestion of sedative or hypnotics confirmed by intravenous flumazenil administration or history taking at the emergency department
  • Absolute contraindication for TH (active severe bleeding and profound shock not controlled by vasoactive drugs)
  • No admission
  • The significant co-ingested drug levels, which are alter the consciousness, is confirmed from the drug analysis lab
  • Pregnancy
  • Burns
  • More than moderate burn or Inhalation burn
  • Burns complicated by other trauma
  • Electrical burn
  • Burns in high risk patients (Patients with chronic underlying diseases (i.e DM, ESRD, liver cirrhosis, etc) which may cause delays or aggravate the wound healing)

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Hypothermia group

Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.

Targeted therapeutic hypothermia is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After TH ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.

Aktywny komparator: Normothermia group

For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.

Targeted therapeutic normothermia will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Main neurocognitive outcome
Ramy czasowe: At 6 months after CO poisoning

Global Deterioration Scale [range 1 - 7 (worst score)]

At 6 months after CO poisoning

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Neurocognitive outcome
Ramy czasowe: At 1 month after CO poisoning

Global Deterioration Scale [range 1 - 7 (worst score)]

At 1 month after CO poisoning
Cerebral Performance Category
Ramy czasowe: At 1 month and 6 months after CO poisoning

Cerebral Performance Category [range 1 - 5 (worst score)]

At 1 month and 6 months after CO poisoning
modified Rankin scale
Ramy czasowe: At 1 month and 6 months after CO poisoning

modified Rankin scale [range 0 - 6 (worst score)]

At 1 month and 6 months after CO poisoning
Glasgow outcome scale
Ramy czasowe: At 1 month and 6 months after CO poisoning

Glasgow outcome scale [range 1 (worst score) - 5]

At 1 month and 6 months after CO poisoning
mini-mental status exam
Ramy czasowe: At 1 month and 6 months after CO poisoning

mini-mental status exam

At 1 month and 6 months after CO poisoning
Korean version of the Modified Barthel Index
Ramy czasowe: At 1 month and 6 months after CO poisoning

Korean version of the Modified Barthel Index

At 1 month and 6 months after CO poisoning
Mortality in intensive care unit
Ramy czasowe: Through study completion, an average of 6 months

Number of participants with mortality in intensive care unit

Through study completion, an average of 6 months
Mortality in intensive care unit
Ramy czasowe: Through study completion, an average of 6 months

Rate of participants with mortality in intensive care unit

Through study completion, an average of 6 months
In-hospital mortality
Ramy czasowe: Through study completion, an average of 6 months

Number of participants with in-hospital mortality

Through study completion, an average of 6 months
In-hospital mortality
Ramy czasowe: Through study completion, an average of 6 months

Rate of participants with in-hospital mortality

Through study completion, an average of 6 months
Mortality
Ramy czasowe: At 1, 3, and 6 months after CO poisoning

Number of participants with all cause mortality

At 1, 3, and 6 months after CO poisoning
Mortality
Ramy czasowe: At 1, 3, and 6 months after CO poisoning

Rate of participants with all cause mortality

At 1, 3, and 6 months after CO poisoning
Length of stay in intensive care unit and hospital
Ramy czasowe: Through study completion, an average of 6 months

Length of stay in intensive care unit and hospital

Through study completion, an average of 6 months
Pneumonia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Pneumonia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with the diagnosis of pneumonia. Diagnosis is established when the following two criteria are met: 1) the appearance of a new infiltrate or consolidation on chest x-ray; and 2) leukocytosis, or leukopenia, or the significant presence of meaningful bacteria in a sputum culture with the absence of other infections.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Shock
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Shock
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with shock. Diagnosis is diagnosed when a vasopressor is needed to resuscitate the patient and lactate levels exceeded 2.0 mmol/L.

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Bradycardia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with dropped heart rate indicated drug or interventions

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Bradycardia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with dropped heart rate indicated drug or interventions

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypokalemia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum K concentration <3.0 - 2.5 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypokalemia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum K concentration <3.0 - 2.5 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperkalemia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum K concentration >6.0 - 7.0 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperkalemia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum K concentration >6.0 - 7.0 mmol/L

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperglycemia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hyperglycemia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with change (Insulin therapy initiated) in daily management from baseline for serum glucose

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypophosphatemia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypophosphatemia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood and indicated replacement therapy

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypomagnesemia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with serum magnesium <0.9 - 0.7 mg/dL

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Hypomagnesemia
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with serum magnesium <0.9 - 0.7 mg/dL

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged prothrombin Time International Normalized Ratio
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged prothrombin Time International Normalized Ratio
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged activated partial thromboplastin time
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Number of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
Prolonged activated partial thromboplastin time
Ramy czasowe: During the intervention (therapeutic hypothermia or normothermia) period (72 hours)

Rate of participants with >2.5 x upper limit of the normal range and bleeding

During the intervention (therapeutic hypothermia or normothermia) period (72 hours)
S100ß (serum)
Ramy czasowe: Within 14 days after CO exposure

Concentration of S100ß (serum)

Within 14 days after CO exposure
Neuronal specific enolase (serum)
Ramy czasowe: Within 14 days after CO exposure

Concentration of neuronal specific enolase (serum)

Within 14 days after CO exposure
Brain magnetic resonance image (MRI)
Ramy czasowe: Within 14 days after CO exposure

Number of participants with brain injury in brain MRI

Within 14 days after CO exposure
Brain magnetic resonance image (MRI)
Ramy czasowe: Within 14 days after CO exposure

Rate of participants with brain injury in brain MRI

Within 14 days after CO exposure

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Współpracownicy

Śledczy

  • Główny śledczy: Yong Sung Cha, MD, Wonju Severance Christian Hospital

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

25 października 2021

Zakończenie podstawowe (Rzeczywisty)

7 listopada 2025

Ukończenie studiów (Rzeczywisty)

7 listopada 2025

Daty rejestracji na studia

Pierwszy przesłany

1 lipca 2021

Pierwszy przesłany, który spełnia kryteria kontroli jakości

13 lipca 2021

Pierwszy wysłany (Rzeczywisty)

26 lipca 2021

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

8 listopada 2026

Ostatnia weryfikacja

1 czerwca 2025

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • TTM-COHB trial
  • CR220011 (Inny identyfikator: Wonju Severance Christian Hospital)
  • 2021-04-043 (Inny identyfikator: Inha University Hospital)

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .